Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 4, 2024
Reporting Period: Event-based report regarding a specific corporate announcement.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Item 8.01 Other Events: The Company announced a late-breaking oral presentation of Phase 1 expansion results for its investigational drug, IDE397. The presentation is scheduled for the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23–25, 2024, in Barcelona, Spain. The results pertain to MTAP-deletion lung and urothelial cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the upcoming presentation of clinical data. No specific financial guidance, forward-looking revenue projections, or risk factor updates are included in the text of this specific 8-K form.
Investor Verification Checklist
- Verify the content of the press release filed as Exhibit 99.1 for specific clinical data points regarding IDE397.
- Confirm the date and location of the EORTC-NCI-AACR Symposium (October 23–25, 2024, Barcelona, Spain).
- Review the Company's most recent 10-Q or 10-K for current financial status, as this 8-K contains no financial metrics.
- Monitor subsequent filings for the actual results of the Phase 1 expansion presentation.